SLS logo

SELLAS Life Sciences (SLS) Company Overview

Profile

Full Name:

SELLAS Life Sciences Group, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 12, 2008

Indexes:

Not included

Website:

http://www.sellaslifesciences.com

Description:

SELLAS Life Sciences is a biopharmaceutical company focused on developing innovative cancer treatments. They work on immunotherapies and personalized medicine to improve patient outcomes. Their goal is to advance therapies that can effectively target and fight various types of cancer.

Key Details

Price

$1.27

Market Cap

$99.79 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$1.34(+37.09% YoY)

PE Ratio

-

Annual ROE

468.15%

Annual Debt To Equity

-0.11

Beta

0.17

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 23, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 8, 2019

Analyst ratings

Recent major analysts updates

Nov 22, 23 Cantor Fitzgerald
Overweight
Sep 7, 23 Cantor Fitzgerald
Overweight
Nov 15, 22 Alliance Global Partners
Buy
Jun 28, 22 Cantor Fitzgerald
Overweight
Jul 21, 21 Cantor Fitzgerald
Overweight
Nov 18, 19 Oppenheimer
Outperform
Nov 18, 19 Maxim Group
Buy
Nov 18, 19 H.C. Wainwright
Buy
Nov 18, 19 Alliance Global Partners
Buy
Nov 15, 19 Maxim Group
Buy

Screeners with SLS included

Growing Shares Outstanding
US stocks
Most recommended stocks
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$1.27
SLS price is $1.27

Price All-time High

$408000.00
SLS price is currently -100.00% below its historical high of $408000.00

Price Analysts Target

$6.00
SLS price is currently -78.83% lower than the consensus analysts' forecast

Price Most Recent Change

-3.79%
SLS price was down -3.79% on Feb 22, 2025

Price YTD Change

+20.97%
SLS price is up +20.97% since January 1st

Price 3-Year Change

-79.48%
SLS price is down -79.48% over the past 3 years

Market cap

Market Cap

$99.79 M
SLS market capitalization is $99.79 million

Market Cap 3-Year Change

+1.42%
SLS market capitalization is up +1.42% over the past 3 years

Market Cap All-time High

$807.84 M
SLS market capitalization is currently -87.65% below its historical high of $807.84 million

Market Cap Sector Rank

46.1%
SLS market capitalization is higher than 46.1% of companies in Healthcare sector

Technical

Beta

0.17
SLS beta is 0.17

200-day SMA

$1.22
SLS price is currently +4.33% above its 200-day simple moving average

14-day RSI

50.95
SLS 14-day relative strength index is 50.95

30-day Relative Volume

0.34
SLS 30-day relative volume is 0.34

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
SLS annual revenue value is unknown

Annual Revenue Analysts Estimate

-
SLS annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
SLS annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
SLS annual revenue is unknown

Profit

Annual Gross Profit

$0.00
SLS annual gross profit is $0.00

Annual Gross Margin

-
SLS annual gross profit margin value is unknown

Annual Operating Profit

-$37.87 M
SLS annual operating income is -$37.87 million

Annual Operating Margin

-
SLS annual operating profit margin value is unknown

Annual Net Income

-$37.34 M
SLS annual net profit is -$37.34 million

Annual Net Margin

-
SLS annual net profit margin value is unknown

EPS

Annual EPS

-$1.34
SLS annual earnings per share is -$1.34

Annual EPS Analysts Estimate

-$0.54
SLS annual earnings per share is currently +149.67% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+37.09%
SLS annual earnings per share is up +37.09% year-on-year

Annual EPS Sector Rank

53.73%
SLS annual earnings per share is higher than 53.73% of companies in Healthcare sector

ROA & ROE

Annual ROA

-600.42%
SLS annual return on assets is -600.42%

Annual ROE

468.15%
SLS annual return on equity is 468.15%

EBIT & EBITDA

Annual EBIT

-$37.87 M
SLS annual earnings before interest & taxes is -$37.87 million

Annual EBITDA

-$37.87 M
SLS annual EBITDA is -$37.87 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
SLS price to earnings ratio value is unknown

PE Ratio Sector Rank

-
SLS price to earnings ratio is unknown

PB Ratio

PB Ratio

6.28
SLS price to book ratio is 6.28

PB Ratio Sector Rank

85.83%
SLS price to book ratio is higher than 85.83% of companies in Healthcare sector

PS Ratio

PS Ratio

-
SLS price to sales ratio value is unknown

PS Ratio Sector Rank

-
SLS price to sales ratio is unknown

Enterprise value

Enterprise Value

$79.34 M
SLS enterprise value is $79.34 million

Enterprise Value Sector Rank

45.89%
SLS enterprise value is higher than 45.89% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.42
SLS EV/EBITDA is -2.42

EV/EBITDA Sector Rank

35.22%
SLS EV/EBITDA is higher than 35.22% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

0.23
SLS annual current ratio is 0.23

Annual Quick Ratio

-
SLS annual quick ratio value is unknown

Leverage

Annual Debt To Equity

-0.11
SLS annual debt to equity ratio is -0.11

Annual Interest Coverage Ratio

-
SLS annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
SLS piotroski f-score value is unknown

Altman Z-Score

-
SLS altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$6.22 M
SLS annual total assets is $6.22 million

Annual Non Current Assets

$3.05 M
SLS annual long term assets is $3.05 million

Annual Current Assets

$3.17 M
SLS annual total current assets is $3.17 million

Annual Cash & Cash Equivalents

$2.53 M
SLS annual cash & cash equivalents is $2.53 million

Equity

Annual Book Value

-$7.98 M
SLS annual book value is -$7.98 million

Annual Working Capital

-$10.56 M
SLS annual working capital is -$10.56 million

Liabilities

Annual Total Liabilities

$14.20 M
SLS annual total liabilities is $14.20 million

Annual Total Long Term Liabilities

$460.00 K
SLS annual total long term liabilities is $460.00 thousand

Annual Current Liabilities

$13.73 M
SLS annual total current liabilities is $13.73 million

Annual Accounts Payable

$5.64 M
SLS annual accounts payable is $5.64 million

Debt

Annual Total Debt

$906.00 K
SLS annual total debt is $906.00 thousand

Annual Total Debt 1-Year Change

-4.13%
SLS annual total debt is down -4.13% year-on-year

Annual Long Term Debt

$460.00 K
SLS annual long term debt is $460.00 thousand

Annual Short Term Debt

$446.00 K
SLS annual short term debt is $446.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$37.87 M
SLS annual total expenses is $37.87 million

Annual Operating Expenses

$37.87 M
SLS annual total operating expenses is $37.87 million

Annual Cost Of Goods Sold

-
SLS annual cost of goods sold value is unknown

Annual SGA

$13.86 M
SLS annual SGA is $13.86 million

Annual D&A

-
SLS annual depreciation & amortization value is unknown

Annual Interest Expense

-
SLS annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$31.41 M
SLS annual cash flow from operations is -$31.41 million

Annual CFO 1-Year Change

-31.92%
SLS annual cash flow from operations is down -31.92% year-on-year

Annual CFI

-$5.50 M
SLS annual cash flow from investing activities is -$5.50 million

Annual CFI 1-Year Change

-22.22%
SLS annual cash flow from investing activities is down -22.22% year-on-year

Annual CFF

$22.32 M
SLS annual cash flow from financing activities is $22.32 million

Annual CFF 1-Year Change

-7.33%
SLS annual cash flow from financing activities is down -7.33% year-on-year

Free CashFlow

Annual FCF

-$36.91 M
SLS annual free cash flow is -$36.91 million

Annual FCF 1-Year Change

-30.38%
SLS annual free cash flow is down -30.38% year-on-year

CAPEX

Annual CAPEX

-
SLS annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
SLS annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

CRBP logo
Corbus Pharmaceuticals Holdings (CRBP)
AKYA logo
Akoya Biosciences (AKYA)
SY logo
So-Young International (SY)
ATOS logo
Atossa Therapeutics (ATOS)
Alpha Cognition (ACOG)
CRDL logo
Cardiol Therapeutics (CRDL)
CAMP logo
CAMP4 Therapeutics (CAMP)
CABA logo
Cabaletta Bio (CABA)
Climb Bio (CLYM)

FAQ

  • What is the ticker symbol for SELLAS Life Sciences?
  • Does SELLAS Life Sciences pay dividends?
  • What sector is SELLAS Life Sciences in?
  • What industry is SELLAS Life Sciences in?
  • What country is SELLAS Life Sciences based in?
  • When did SELLAS Life Sciences go public?
  • Is SELLAS Life Sciences in the S&P 500?
  • Is SELLAS Life Sciences in the NASDAQ 100?
  • Is SELLAS Life Sciences in the Dow Jones?
  • When was SELLAS Life Sciences's last earnings report?
  • When does SELLAS Life Sciences report earnings?
  • Should I buy SELLAS Life Sciences stock now?

What is the ticker symbol for SELLAS Life Sciences?

The ticker symbol for SELLAS Life Sciences is NASDAQ:SLS

Does SELLAS Life Sciences pay dividends?

No, SELLAS Life Sciences does not pay dividends

What sector is SELLAS Life Sciences in?

SELLAS Life Sciences is in the Healthcare sector

What industry is SELLAS Life Sciences in?

SELLAS Life Sciences is in the Biotechnology industry

What country is SELLAS Life Sciences based in?

SELLAS Life Sciences is headquartered in United States

When did SELLAS Life Sciences go public?

SELLAS Life Sciences's initial public offering (IPO) was on March 12, 2008

Is SELLAS Life Sciences in the S&P 500?

No, SELLAS Life Sciences is not included in the S&P 500 index

Is SELLAS Life Sciences in the NASDAQ 100?

No, SELLAS Life Sciences is not included in the NASDAQ 100 index

Is SELLAS Life Sciences in the Dow Jones?

No, SELLAS Life Sciences is not included in the Dow Jones index

When was SELLAS Life Sciences's last earnings report?

SELLAS Life Sciences's most recent earnings report was on Nov 13, 2024

When does SELLAS Life Sciences report earnings?

The next expected earnings date for SELLAS Life Sciences is May 14, 2025

Should I buy SELLAS Life Sciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions